Literature DB >> 23665535

Improvement of insulin resistance following transsphenoidal surgery in patients with acromegaly: correlation with serum IGF-I levels.

K Mori1, Y Iwasaki, Y Kawasaki-Ogita, S Honjo, Y Hamamoto, H Tatsuoka, K Fujimoto, H Ikeda, Y Wada, Y Takahashi, J Takahashi, H Koshiyama.   

Abstract

AIM: The aim of this study was to determine the correlation between the growth hormone (GH)-insulin-like growth factor-I (IGF-I) axis and glucose intolerance in acromegaly during the early postoperative period. SUBJECTS AND METHODS: The study included 20 patients with acromegaly caused by GH-secreting pituitary adenoma who received transsphenoidal surgery in our hospital. Glucose tolerance was evaluated with oral glucose tolerance tests (OGTTs) performed during pre- and early postoperative periods (9 [7-18] days after surgery). Homeostasis model assessment of insulin resistance (HOMA-IR) and insulinogenic index (IGI) were calculated, and correlation analyses were performed between these values and the GH-IGF-I axis. Patients were divided according to postoperative changes of the axis, and glucose tolerance was compared between the groups.
RESULTS: In preoperative OGTTs, nine patients had impaired glucose tolerance and two had diabetes mellitus patterns. Postoperatively, significant reduction was observed both in fasting plasma glucose levels (p<0.01) and in HOMA-IR (p<0.01), whereas IGI showed no significant change. HOMA-IR was significantly correlated with serum IGF-I levels both before (r=0.83, p<0.01) and after (r=0.57, p<0.01) surgery, although it was not correlated with serum GH levels. Patients who achieved more than 50% postoperative reduction in serum IGF-I levels showed significant improvement in OGTTs results (p<0.05).
CONCLUSIONS: In patients with acromegaly, serum IGF-I levels, but not GH levels, were significantly correlated with insulin resistance. Early postoperative improvement of glucose tolerance is observed in patients who achieved postoperative reduction in serum IGF-I levels.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23665535     DOI: 10.3275/8964

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  27 in total

1.  Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity.

Authors:  S Yakar; J L Liu; A M Fernandez; Y Wu; A V Schally; J Frystyk; S D Chernausek; W Mejia; D Le Roith
Journal:  Diabetes       Date:  2001-05       Impact factor: 9.461

2.  Standardized centile curves and reference intervals of serum insulin-like growth factor-I (IGF-I) levels in a normal Japanese population using the LMS method.

Authors:  Tsuyoshi Isojima; Akira Shimatsu; Susumu Yokoya; Kazuo Chihara; Toshiaki Tanaka; Naomi Hizuka; Akira Teramoto; Ke-ita Tatsumi; Katsuhiko Tachibana; Noriyuki Katsumata; Reiko Horikawa
Journal:  Endocr J       Date:  2012-05-19       Impact factor: 2.349

3.  Insulin resistance in the liver-specific IGF-1 gene-deleted mouse is abrogated by deletion of the acid-labile subunit of the IGF-binding protein-3 complex: relative roles of growth hormone and IGF-1 in insulin resistance.

Authors:  Martin Haluzik; Shoshana Yakar; Oksana Gavrilova; Jennifer Setser; Yves Boisclair; Derek LeRoith
Journal:  Diabetes       Date:  2003-10       Impact factor: 9.461

4.  Early postoperative indicators of late outcome in acromegalic patients.

Authors:  Jun A Takahashi; Akira Shimatsu; Kazuwa Nakao; Nobuo Hashimoto
Journal:  Clin Endocrinol (Oxf)       Date:  2004-03       Impact factor: 3.478

5.  Recombinant human insulin-like growth factor-I therapy improves glycemic control and insulin action in the type A syndrome of severe insulin resistance.

Authors:  L A Morrow; M B O'Brien; D E Moller; J S Flier; A C Moses
Journal:  J Clin Endocrinol Metab       Date:  1994-07       Impact factor: 5.958

Review 6.  Guidelines for acromegaly management: an update.

Authors:  S Melmed; A Colao; A Barkan; M Molitch; A B Grossman; D Kleinberg; D Clemmons; P Chanson; E Laws; J Schlechte; M L Vance; K Ho; A Giustina
Journal:  J Clin Endocrinol Metab       Date:  2009-02-10       Impact factor: 5.958

Review 7.  Roles of insulin-like growth factor-I and growth hormone in mediating insulin resistance in acromegaly.

Authors:  David Robert Clemmons
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

8.  Growth hormone regulation of p85alpha expression and phosphoinositide 3-kinase activity in adipose tissue: mechanism for growth hormone-mediated insulin resistance.

Authors:  Juan-Pablo del Rincon; Keiji Iida; Bruce D Gaylinn; Carrie E McCurdy; J Wayne Leitner; Linda A Barbour; John J Kopchick; Jacob E Friedman; Boris Draznin; Michael O Thorner
Journal:  Diabetes       Date:  2007-03-15       Impact factor: 9.461

9.  Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice.

Authors:  Shoshana Yakar; Jennifer Setser; Hong Zhao; Bethel Stannard; Martin Haluzik; Vaida Glatt; Mary L Bouxsein; John J Kopchick; Derek LeRoith
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

10.  Comparison of the metabolic effects of recombinant human insulin-like growth factor-I and insulin. Dose-response relationships in healthy young and middle-aged adults.

Authors:  S D Boulware; W V Tamborlane; N J Rennert; N Gesundheit; R S Sherwin
Journal:  J Clin Invest       Date:  1994-03       Impact factor: 14.808

View more
  5 in total

Review 1.  Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly.

Authors:  M G Baroni; F Giorgino; V Pezzino; C Scaroni; A Avogaro
Journal:  J Endocrinol Invest       Date:  2015-12-30       Impact factor: 4.256

2.  Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bicêtre cohort, and review of the literature.

Authors:  Claire Briet; Mirela Diana Ilie; Emmanuelle Kuhn; Luigi Maione; Sylvie Brailly-Tabard; Sylvie Salenave; Bertrand Cariou; Philippe Chanson
Journal:  Endocrine       Date:  2018-11-05       Impact factor: 3.633

3.  HOMA-IR in acromegaly: a systematic review and meta-analysis.

Authors:  Betina Biagetti; Anna Aulinas; Anna Casteras; Santiago Pérez-Hoyos; Rafael Simó
Journal:  Pituitary       Date:  2020-10-21       Impact factor: 4.107

4.  Domino effect of pituitary growth hormone tumor complicated by diabetic ketoacidosis and pituitary apoplexy: a case report.

Authors:  JinYu Pan; XiangHong Yang; Wei Zhu
Journal:  BMC Endocr Disord       Date:  2021-05-26       Impact factor: 2.763

5.  Postoperative Changes in Metabolic Parameters of Patients with Surgically Controlled Acromegaly: Assessment of New Stringent Cure Criteria.

Authors:  Masanori Yonenaga; Shingo Fujio; Mika Habu; Hiroshi Arimura; Takaaki Hiwatari; Shunichi Tanaka; Yasuyuki Kinoshita; Hiroshi Hosoyama; Hirofumi Hirano; Kazunori Arita
Journal:  Neurol Med Chir (Tokyo)       Date:  2018-02-23       Impact factor: 1.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.